The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

white-paper
The New Chemistry, Manufacturing, and Controls (CMC) Regulations in China
Read More

post
Why FDA PreCheck is a game-changer for small & mid-sized pharma — and how these companies should lean in
Read More

white-paper
Solid-Phase Oligonucleotide Synthesis (SPOS) and Liquid-Phase Oligonucleotide Synthesis (LPOS): Complementary or Competitive Processes?
Read More

white-paper
BioPharma Due Diligence in a Shifting Global Market
Read More
Let's move from science to success.
Let’s Talk